maps • volume xv number 3 • Winter 2005
 Copyright © 2005 The New York Times
Saturday, August 27th, 2005
 
 

Marijuana Pipe Dreams

John Tierney

When the Supreme Court ruled in June that states could not legalize marijuana for medical uses, Justice Stephen Breyer voted with the majority. But during oral arguments, he suggested an alternative way for patients to get it: let the federal Food and Drug Administration decide if marijuana should be a prescription drug.

"Medicine by regulation is better than medicine by referendum," he said. In theory, that sounds reasonable. But what if the officials doing the regulation are afflicted with a bad case of Reefer Madness?

If you doubt this possibility, you should have been at a hearing that began this week at the Drug Enforcement Administration's headquarters. Lyle Craker, a professor of plant and soil sciences at the University of Massachusetts, asked an administrative judge to overrule the agency so he could grow marijuana for F.D.A.-approved research projects by other scientists.

Dr. Craker is a well-regarded agronomist who's being supported by the American Civil Liberties Union and both of his senators, Edward Kennedy and John Kerry. But for four years he's been stymied by the D.E.A., which first stalled and then finally denied his request for a permit.

There are precedents for his re quest, because researchers already get supplies of other drugs - like heroin, LSD and Ecstasy - from independent laboratories licensed to make them. But researchers who want marijuana have only one legal source: a crop grown in Mississippi and dispensed by the National Institute on Drug Abuse.

Scientists say they need an alternative partly because the government's marijuana is of such poor quality - too many seeds and stems - and partly because the federal officials are so loath to give it out for research into its medical benefits.

Discovering benefits, after all, would undermine the great anti-marijuana campaign that has taken hold in Washington. Marijuana is deemed to be such a powerful "gateway" to other drugs that it's become the top priority in the federal drug war, much to the puzzlement of many scientists, not to mention the police officers who see a lot of worse drugs on the streets.

People with glaucoma and AIDS have sworn by the efficacy of marijuana, and there have been studies by state health departments showing that smoking marijuana is especially good at controlling nausea. Scientists would like to test these effects, but they can't do good studies until they get good marijuana.

Critics of medical marijuana say that it's unnecessary because patients can obtain the benefits of its active ingredient, THC, through a drug that's already available, Marinol. But many patients say it doesn't work as well. They point to the case of the writer Peter McWilliams, who said smoking marijuana was the only way to control the nausea brought on by the mix of drugs he took for AIDS and cancer.

He was forced to switch to Marinol after a D.E.A. investigation led to his conviction for violating federal laws against marijuana. In 2000, several weeks before he was to be sentenced, he was found dead in his bathroom. He had choked on his own vomit.

Phillip Alden, a writer living in Redwood City, Calif., told me that marijuana was a godsend for him in dealing with the effects of AIDS. He said it eased excruciating pains in his fingertips, controlled nausea and enabled him to avoid the wasting syndrome that afflicts AIDS patients who are unable to eat enough food.

But Mr. Alden said only some kinds of marijuana worked - not the weak variety provided by the federal government, which he smoked during a research study.

"It was awful stuff," he said. "They started out with a very low-grade plant, rolled it up with stems and seeds, and then freeze-dried it so that they probably ruined any of the THC crystals. All it did was give me headaches and bronchitis. The bronchitis got so bad I had to drop out of the study."

Mr. Alden was scheduled to testify at this week's hearing, but he told me he had to withdraw because the D.E.A. refused to give him legal immunity if he admitted using marijuana not from the government. It's a shame the judge will be making a decision without hearing him, but I can understand Mr. Alden's hesitancy.

D.E.A. officials have already shown they're quite capable of persecuting someone who uses marijuana to deal with AIDS, and they may well be even more eager to go after someone who encourages research into their least favorite drug. When it comes to marijuana research, the federal policy is "Just Say Know-Nothing."

 


 

 




Summer 2009 Vol. 19, No. 2 MAPS Research Update 2009
Spring 2009 Vol. 19, No. 1 Special Edition: Psychedelics and Ecology
Winter 2008/09 Vol. 18, No. 3 MAPS 2008 Financial Report
Summer 2008 Vol. 18, No. 2 Phoenix Rising: A Review of MAPS Research
Spring 2008 Vol. 18, No. 1 Special Edition: Technology and Psychedelics
Winter 2007 Vol. 17, No. 3 MAPS 06-07 Fiscal Yearly Report
Autumn 2007 Vol. 17, No. 2 Special Edition: Psychedelics and Self-Discovery
Spring/Summer 2007 Vol. 17, No. 1 The Chrysalis Stage
Winter 2006-7 Vol. 16, No. 3 Low Maintenance/High Performance
Autumn 2006 Vol. 16, No. 2 Technologies of Healing
Spring 2006 Vol. 16, No. 1 MAPS' 20th Anniversary
Winter 2005 Vol. 15, No. 3 MAPS final year as a teenager
Summer 2005 Vol. 15, No. 2 Israel Conference: MDMA/PTSD Research
Spring 2005 Vol. 15, No. 1 Accelerating flow of work and time
Autumn 2004 Vol. 14, No. 2 Rites of Passage: Kids and Psychedelics
Summer 2004 Vol. 14, No. 1 10 stamps and $250,000
Winter 2003 Vol. 13, No. 2 Holy Fire
Spring 2003 Vol. 13, No. 1 60th Anniversary of the Discovery of LSD
Autumn 2002 Vol. 12, No. 3 Vision
Summer 2002 Vol. 12, No. 2 "From celebration to frustration, and back again."
Spring 2002 Vol. 12, No. 1 Sex, Spirit & Psychedelics 2002
Autumn 2001 Vol. 11, No. 2 "In the future, it will be called Despair."
Spring 2001 Vol. 11, No. 1 "A Tidal Wave of Ecstasy!"
Autumn 2000 Vol. 10, No. 3 Creativity 2000
Summer 2000 Vol. 10, No. 2 Endings and Beginnings
Spring 2000 Vol. 10, No. 1 Making History in Slow Motion
Winter 1999/00 Vol. 9, No. 4 To the Ends of the Earth for MDMA Research...
Autumn 1999 Vol. 9, No. 3 MAPS' long-standing efforts to conduct...
Summer 1999 Vol. 9, No. 2 MAPS has come full circle...
Spring 1999 Vol. 9, No. 1 Patience, persistence and passion
Winter 1998/99 Vol. 8, No. 4 One of special pleasures of directing MAPS...
Autumn 1998 Vol. 8, No. 3 The Ayahuasca Issue (with Hofmann interview)
Summer 1998 Vol. 8, No. 2 Emotionally Powerful Anecdotes...
Spring 1998 Vol. 8, No. 1 Death Has a Way of Focusing One's Attention
Autumn 1997 Vol. 7, No. 4 Celebration is in Order
Summer 1997 Vol. 7, No. 3 Time Horizons
Spring 1997 Vol. 7, No. 2 Synchronicity
Winter 1996/97 Vol. 7, No. 1 Learning to Crawl
Autumn 1996 Vol. 6, No. 4 An Invitation for Dialogue
Summer 1996 Vol. 6, No. 3 Budding Research
New Year 1996 Vol. 6, No. 2 Sending Down Roots
Autumn 1995 Vol. 6, No. 1 Baby Steps
Summer 1995 Vol. 5, No. 4 Opportunity Amidst Obstacles
Winter 1994/95 Vol. 5, No. 3 Clinical Trials and Tribulations
Autumn 1994 Vol. 5, No. 2 Building Towards Clinical Trials
Summer 1994 Vol. 5, No. 1 Politics and Protocols: In Search of a Balance
Spring 1994 Vol. 4, No. 4 Laying the Groundwork
Winter 1993/94 Vol. 4, No. 3 A Time of Tests
Summer 1993 Vol. 4, No. 2 So Close Yet So Far
Spring 1993 Vol. 4, No. 1 Remembrance and Renewal
Winter 1992/93 Vol. 3, No. 4 Forging New Alliances
Summer 1992 Vol. 3, No. 3 Building on Common Ground
Spring 1992 Vol. 3, No. 2 Small Steps, Gradual Progress, New Opportunities
Winter 1991/92 Vol. 3, No. 1 The Rekindling of a Thousand Points of Light
Summer 1991 Vol. 2, No. 2 MDMA protocol development with cancer patients
Winter 1990/91 Vol. 2, No. 1 MAPS' Swiss pharmacologically-assisted psychotherapy conference
Autumn 1990 Vol. 1, No. 3 What and Who is MAPS?
Summer 1989 Vol. 1, No. 2 Switzerland Leads the Way
Summer 1988 Vol. 1, No. 1 MDMA can become a legal medicine